Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Cabometyx

- PMLiVE

BMS presents positive four-year results for Opdivo combination in lung cancer

NSCLC is the most common type of lung cancer, representing up to 85% of diagnoses

- PMLiVE

Oncology eBook: Reducing the care gap in cancer prevention, diagnosis, and treatment

Despite significant innovation in the oncology landscape, there is a growing care gap preventing patients accessing and benefiting from innovations in cancer treatment. In this new publication, our oncology experts...

Avalere Health

- PMLiVE

BMS and Janssen’s antithrombotic granted FDA fast track designation

The three indications include ischaemic stroke, acute coronary syndrome and atrial fibrillation

- PMLiVE

Bristol Myers Squibb presents positive results for idiopathic pulmonary fibrosis drug

About 100,000 people are living with the progressive condition in the US alone

- PMLiVE

Researchers at ICR London discover new nutrient source for cancer growth

Study reveals new findings of dietary changes within pancreatic cancer cells

- PMLiVE

AstraZeneca announces positive phase 3 results for Tagrisso combination in lung cancer

An estimated 2.2 million people worldwide are diagnosed with lung cancer each year

- PMLiVE

Bristol Myers Squibb’s Sotyktu approved by MHRA for plaque psoriasis

Up to 1.8 million people in the UK are affected by some form of the inflammatory condition

- PMLiVE

Bristol Myers Squibb and Tubulis partner in deal worth over $1bn

The agreement is aimed at developing differentiated ADCs for solid tumours

- PMLiVE

ICR and NeoPhore announce immuno-oncology collaboration to develop new cancer drugs

The partners will evaluate the effect of NeoPhore’s small molecule inhibitors on tumours

- PMLiVE

Incyte and Biotheryx collaborate to develop protein degraders for oncology targets

Biotheryx will receive up to $347m in potential milestone payments

- PMLiVE

NICE publishes draft guidance not recommending Ipsen’s Cabometyx for thyroid cancer

Up to 15% of patients with differentiated thyroid cancer do not respond to radioactive iodine

- PMLiVE

BioNTech and Duality Biologics partner in deal worth over $1.5bn

The companies will co-develop two antibody-drug conjugates for solid tumours

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links